Imatinib Demo (Imatinib Mesilate)

Imatinib Mesilate blocks the ATP‑binding pocket of BCR‑ABL, KIT and PDGFR tyrosine kinases. By preventing phosphorylation of downstream proteins, it stops the signaling pathways that promote uncontrolled proliferation of malignant cells, leading to tumor regression.

The exact dose of Imatinib Demo is individualized by the prescribing physician based on the specific diagnosis, disease stage, patient weight, renal and hepatic function, and any concomitant therapies. No fixed regimen is provided here.

Data on Imatinib use in pregnancy and lactation are limited, and animal studies suggest potential risk to the fetus. Consequently, the drug is generally avoided in pregnant or nursing women unless the potential benefit justifies the risk.

To place an order, submit an enquiry on the Imatinib Demo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard first‑line option. Second‑generation agents such as dasatinib and nilotinib offer higher potency and may be chosen for patients with resistance or intolerance to imatinib, but they also have distinct safety profiles.

Imatinib Demo should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept tightly closed, protected from moisture and direct sunlight to maintain product stability.

Imatinib Demo is taken orally, usually with a glass of water. It can be taken with or without food, but consistent administration with respect to meals helps maintain steady drug levels. Swallow tablets whole; do not crush or chew unless instructed otherwise.

The most critical adverse events include severe neutropenia, which can predispose to infections; hepatotoxicity, manifested by elevated liver enzymes or jaundice; and cardiac failure, presenting as shortness of breath, edema or reduced exercise tolerance. Prompt medical evaluation is required if these occur.

Patients with known hypersensitivity to imatinib or any of its excipients should avoid the drug. Those with severe hepatic impairment, uncontrolled cardiac disease, or who are pregnant without a compelling indication should also be excluded, unless a specialist determines the benefits outweigh the risks.